AHK-Cu100mg
AHK-Cu Canada — 100 mg Lyophilized Vials
Copper-Binding Tripeptide Complex
AHK-Cu is a copper complex of the tripeptide alanyl-histidyl-lysine. The peptide portion coordinates a copper(II) ion, and the material is supplied as a lyophilized solid for laboratory research only.
Mix & Match
1 vial — no vial discount yet.
Add 2 more vials for 5% off.
After that, 10% at 5 vials, 20% at 10 vials.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
AHK-Cu is a copper complex of the tripeptide alanyl-histidyl-lysine. The peptide portion coordinates a copper(II) ion, and the material is supplied as a lyophilized solid for laboratory research only.
The published record for AHK-Cu is limited. Reported work has examined tripeptide-copper complexes in cultured human hair follicle systems, looking at follicular cell behaviour under in vitro conditions.
AHK-Cu belongs to a small group of short histidine-containing peptides that form stable coordination complexes with divalent copper. Interest in these complexes has centred on the copper ion being delivered in a peptide-bound form, and on how that form interacts with cultured cells. The mechanism of AHK-Cu itself is not well characterised in the published literature, and descriptions of its activity are largely extrapolated from the broader class of copper-peptide complexes rather than established for this molecule specifically.
Reported in vitro research has used human hair follicle culture models, with endpoints including follicle elongation and the behaviour of dermal papilla cells. These are isolated tissue and cell-culture measurements. Beyond this, systematic pharmacological characterisation of AHK-Cu, including receptor-level or pathway-level work, does not appear in the candidate literature.
AHK-Cu emerged from work on short copper-binding peptides, a field that developed from observations that histidine-containing tripeptides form defined complexes with copper(II). The precise origin of AHK-Cu as a distinct research compound is not well documented in the available literature.
The research record has remained narrow. Published investigation of tripeptide-copper complexes in human hair follicle culture provides the main documented experimental context, and no broader body of preclinical or clinical literature on AHK-Cu is available among the candidate references.
Laboratory work involving AHK-Cu sits within research on copper-peptide coordination complexes and their behaviour in cultured tissue systems. The documented framework is in vitro human hair follicle culture, where follicular growth measurements and dermal papilla cell responses have been assessed. The published record is thin, and findings are confined to isolated culture conditions rather than characterised mechanism.
3 of the 4 areas below are addressed directly by a paper cited on this page.
Addressed on this page by Pyo 2007. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Pyo 2007. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
No paper cited on this page reports on dermal, papilla or cell. This heading marks where AHK-Cu is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Addressed on this page by Pyo 2007. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
The references section of this page cites 1 primary paper published in 2007 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
AHK-Cu is frequently listed as a peptide by suppliers in this market. It is not one. The structure published on this page is the compound's actual chemistry, and research on it should be read against its own class rather than against peptide literature.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for AHK-Cu, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
AHK-Cu is commonly described online in connection with faster healing from injury and improved recovery. In the research literature the same compound is filed under copper-peptide coordination chemistry, in vitro human hair follicle culture models and dermal papilla cell studies.
The 1 paper cited on this page, published in 2007 describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Presented alongside compounds with decades of published research, as though the evidence base is comparable.
It is not. AHK-Cu rests on 1 cited paper (in 2007). A record that thin cannot support conclusions about mechanism, effect or safety, and the honest reading is that this compound has been studied very little rather than studied and validated.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for AHK-Cu is per lot, not per product. The current 100mg lot AHKC-CA-26H-100 returned 99.33 mg measured, 99.3% of the labelled 100 mg, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.
Purity is half the number. It states what fraction of the material in the vial is AHK-Cu; it says nothing about how much material is in the vial, and a short-filled vial can return a purity result that is entirely accurate. The figure that answers the second question is measured mass against expected content — for AHK-Cu, this lot measured 99.3% of its labelled 100 mg. Where a lot comes in under 100% that is published too: 100mg at 99.3%. A supplier who only publishes flattering numbers has not told you anything.
The lot code printed on the vial matches the code on the certificate for AHK-Cu. Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.
Researchers who buy AHK-Cu in Canada through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
AHK-Cu is supplied as lyophilized powder. It is not a peptide, and solvent behaviour follows from its own chemistry rather than from the aqueous-vehicle conventions that apply to peptide material — the published literature for this compound is the reference for solvent selection, not a general peptide protocol.
Dry storage below freezing and protection from light are the general controls. As with any lyophilized material, the powder frequently sits as a thin film at the base of the vial and is easy to mistake for an empty vial before inspection.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each vial contains the labeled quantity of lyophilized AHK-Cu. Independent third-party analysis verifies purity, identity, and net content per batch.
The vial contains only the lyophilized compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Related
Eppix Flash Sale −30%Peptides
Triple GIP / GLP-1 / Glucagon Agonist · 10, 20, 40 & 120 mg Retatrutide is a synthetic peptide developed for controlled laboratory research involving multi-receptor signaling systems. It is structurally designed to interact with GLP-1, GIP, and glucagon receptor pathways within experimental environments.
RETA-CA-26F-1099.637%
11.76 mg / 10 mg
$41.96$59.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
Dual GIP / GLP-1 Agonist · 10, 30 & 65 mg Tirzepatide is a synthetic peptide developed for controlled laboratory research involving dual incretin receptor signaling systems. It is structurally designed to interact with GLP-1 and GIP receptor pathways within experimental environments.
TIRZ-CA-26G-1099.634%
11.42 mg / 10 mg
$24.46$34.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
GLP-1 Receptor Agonist · 10 mg Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone involved in glucose-dependent signaling. It is developed for controlled laboratory investigation within regulated experimental environments.
10 mgSEMA-CA-26F-1099.504%
11.27 mg / 10 mg
$38.46$54.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
Selective Amylin Agonist (LY3841136) · 10 mg This product is supplied as eloralintide (LY3841136), a long-acting, selective amylin receptor agonist studied in research on metabolic and body-weight regulation.
10 mgELOR-CA-26G-1099.810%
12.42 mg / 10 mg
$101.46$144.95CAD
Flash sale ends in
